CARLSBAD, Calif. , Jan. 26, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett , Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research . Dr.
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis’ genetic medicines and commercial readiness
Royalty Pharma to acquire an interest in SPINRAZA ® and pelacarsen royalties — Ionis retains majority of royalties and all milestones from Novartis for pelacarsen Royalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestones Agreement enables Ionis to achieve commercial
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
CARLSBAD, Calif. , Jan. 4, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference at 9:45 a.m.
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
SOD1-ALS affects approximately 2% of people living with ALS worldwide 1 If approved, tofersen would be the world’s first treatment to target a genetic cause of ALS EMA acceptance follows FDA’s acceptance of tofersen NDA earlier this year CARLSBAD, Calif. , Dec.